Exelixis, a biotech company focused on cancer medicines, could potentially double by 2031. While its main product Cabometyx will face generic competition by early 2030, the company's promising pipeline candidate zanzalintinib could reach peak sales of $5 billion across multiple cancer indications, positioning it as a strong successor to drive future growth.

Merck & Co. and Eisai announced that their Phase 3 LITESPARK-012 trial failed to meet primary endpoints for a triplet therapy combining Keytruda, Lenvima, and Welireg for advanced clear cell renal cell carcinoma. The failure caused Merck shares to fall 4.08%. However, the FDA approved Merck's new HIV treatment Idvynso on the same day, and analysts suggest alternative treatment strategies may still be viable.

The article recommends three healthcare stocks trading under $50: Pfizer (PFE) at $27.45 with a low forward P/E of 9x and a strong oncology pipeline; Novo Nordisk (NVO) at $38.43 positioned to capitalize on the expanding weight-loss drug market with products like Wegovy; and Exelixis (EXEL) at $41.80, a focused oncology player with the successful Cabometyx therapy and promising pipeline candidates like zanzalintinib.

Exelixis, a U.S.-based biotech company specializing in cancer treatments, is positioned for market-beating returns through its growing pipeline beyond its blockbuster cabozantinib drug. The company reported 57.9% EPS growth in 2025 and recently received FDA approval for zanzalintinib for metastatic colorectal cancer. With zanzalintinib in four phase 3 trials and strategic partnerships with major pharma companies, Exelixis aims to become a top-five solid tumor oncology company.

InSilico Medicine, fresh from Hong Kong's biggest 2025 IPO raising HK$2.28 billion, announced a multi-year drug discovery partnership with French pharmaceutical company Servier worth up to $888 million. The deal leverages InSilico's AI platform for cancer drug development. Despite strong investor backing and rapid pipeline progress, the company faces profitability challenges with volatile revenue heavily dependent on partnership payments.

The Motley Fool recommends two biotech stocks for long-term investment: Axsome Therapeutics, which has generated strong revenue growth (65.8% YoY through Q3 2025) with approved products and promising late-stage candidates including Auvelity for Alzheimer's disease agitation; and Exelixis, an oncology specialist with its blockbuster drug Cabometyx and an upcoming next-generation cancer medicine Zanzalintinib in phase 3 trials for metastatic colorectal cancer.

The article highlights two biotechnology companies, Therapeutics and Exelixis, as promising investment opportunities for 2026 due to their innovative drug pipelines and potential for significant market growth.

Adagene initiated a Phase 2 clinical trial for muzastotug (ADG126) in combination with KEYTRUDA for microsatellite stable colorectal cancer, randomizing patients to 10 or 20 mg/kg doses with anticipated trial completion in early 2027.

Merck and Eisai reported positive Phase 3 trial results for their cancer therapy combination Welireg and Lenvima in treating advanced renal cell carcinoma, demonstrating significant improvement in progression-free survival compared to rival treatments.

Exelixis is a biotech company with a strong market position in cancer drugs, particularly kidney cancer treatment Cabometyx. The company is profitable, has promising drug candidates like zanzalintinib, and is well-positioned for future growth in oncology.

The pancreatic endocrine tumor market is expected to grow significantly between 2025-2034, driven by novel therapies like Zanzalintinib, RYZ101, and Nab-sirolimus, which could transform treatment approaches for this rare cancer.

Two biotech companies, Axsome Therapeutics and Exelixis, are predicted to potentially outperform the market in the next five years due to strong product portfolios, promising drug pipelines, and potential for significant market expansion in healthcare treatments.